The latest price target for Sanofi (NASDAQ:SNY) was reported by UBS on January 16, 2026. The analyst firm set a price target for $0.00 expecting SNY to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Sanofi (NASDAQ:SNY) was provided by UBS, and Sanofi downgraded their neutral rating.

The last upgrade for Sanofi SA happened on September 8, 2025 when Morgan Stanley raised their price target to $58. Morgan Stanley previously had an equal-weight for Sanofi SA.

The last downgrade for Sanofi SA happened on January 16, 2026 when UBS changed their price target from N/A to N/A for Sanofi SA.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sanofi, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sanofi was filed on January 16, 2026 so you should expect the next rating to be made available sometime around January 16, 2027.

While ratings are subjective and will change, the latest Sanofi (SNY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Sanofi (SNY) is trading at is $48.20, which is out of the analyst’s predicted range.